Last reviewed · How we verify
BNT327 Optimized Dose
BNT327 is a mRNA-based vaccine that encodes for the SARS-CoV-2 spike protein.
BNT327 is a mRNA-based vaccine that encodes for the SARS-CoV-2 spike protein. Used for Prevention of COVID-19.
At a glance
| Generic name | BNT327 Optimized Dose |
|---|---|
| Sponsor | BioNTech SE |
| Drug class | mRNA vaccine |
| Target | SARS-CoV-2 spike protein |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
This vaccine works by inducing an immune response against the SARS-CoV-2 spike protein, which is a key component of the virus. The mRNA-based design allows for rapid production and adaptation to emerging variants.
Approved indications
- Prevention of COVID-19
Common side effects
- Pain, redness, swelling at injection site
Key clinical trials
- A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer (PHASE1, PHASE2)
- Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |